



# THERIOPHARM






## THERIOSOME PLATFORM


**Size 50 to 60 nm**

**Pharmaceutical grade  
excipients**

**+ GRAS components**



# NANOMEDicine Platform



**THERIOSOME**

**ANY THERAPEUTIC application**




**ANY ADMINISTRATION ROUTE**

- IT: intra-tumoral
- IV: intra-venous
- IP: intra-peritoneal


- Oral/enteral

- Other routes: nasal, sublingual, transdermal, rectal, vaginal, pulmonary...

## NANO-drops (50-60nm)



### Calix[6]arene




1,3,5-OCH<sub>3</sub>-2,4,6-OCH<sub>2</sub>R-*p*-*tert*-butylcalix[6]arene  
R = CONHOH (LH<sub>3</sub>) or R = COOH (L'H<sub>3</sub>)

#### *Properties of LH<sub>3</sub>*

- Hydroxamic chelating functions (CONHOH) of LH<sub>3</sub> are supposed to present a very high affinity towards Pu(IV) [1]
- LH<sub>3</sub> has a very good affinity towards uranyl ion thanks to the geometry of the cavity and the chelating groups nature [2]

⇒ LH<sub>3</sub> is supposed to be a promising molecule to extract Pu and U



**Nanoscale brachytherapy**



Targeted Polymeric Nanoparticle





Polymeric Nanoparticle



Stimuli responsive Polymeric Nanoparticle



Injecting nanoparticle based drugs



Representation showing various approaches to drug targeting:

- (a) Passive transport of nanocarriers through the permeable blood vessels of tumor tissue via extravasation;
- (b) Active targeted delivery to cancer cells;
- (c) Adaptive nanomedicines engineered to release anticancer agents in response to internal or external cue

